0 16 eps expected for ironwood pharmaceuticals inc irwd


$-0.16 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD)


May 8, 2018 – By Henry Gaston

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) LogoInvestors sentiment decreased to 1.05 in Q4 2017. Its down 0.20, from 1.25 in 2017Q3. It dived, as 18 investors sold Ironwood Pharmaceuticals, Inc. shares while 44 reduced holdings. 21 funds opened positions while 44 raised stakes. 149.98 million shares or 2.99% less from 154.60 million shares in 2017Q3 were reported.

New York State Common Retirement Fund holds 0.03% or 1.41 million shares. Natl Bank Of New York Mellon Corp stated it has 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Tocqueville Asset Management L P invested 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). California State Teachers Retirement holds 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 212,298 shares. Orbimed Advsrs Ltd Liability Corp accumulated 4.53M shares. First Republic Mngmt holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 35,058 shares. Blackrock Inc accumulated 0.01% or 11.70 million shares. Plante Moran Advsr Ltd Co accumulated 0% or 79 shares. Sector Gamma As invested 2.99% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Thrivent Financial For Lutherans owns 171,386 shares. Iowa-based Principal Inc has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Bailard Inc stated it has 0.02% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Northwestern Mutual Wealth Mgmt has 270 shares. United Kingdom-based Barclays Public Lc has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Dekabank Deutsche Girozentrale reported 58,900 shares.

Since January 24, 2018, it had 0 buys, and 7 selling transactions for $1.22 million activity. $21,090 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares were sold by McHugh Julie. OLANOFF LAWRENCE S also sold $28,100 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, March 5. Shares for $23,954 were sold by Currie Mark G on Wednesday, February 21. $49,008 worth of stock was sold by MCCOURT Thomas A on Wednesday, February 21. 7,741 shares were sold by Gilbert Halley E, worth $113,483.

Analysts expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report $-0.16 EPS on May, 14.They anticipate $0.17 EPS change or 51.52 % from last quarter’s $-0.33 EPS. After having $-0.14 EPS previously, Ironwood Pharmaceuticals, Inc.’s analysts see 14.29 % EPS growth. The stock decreased 3.34% or $0.62 during the last trading session, reaching $17.97. About 1.15M shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 11.53% since May 8, 2017 and is downtrending. It has underperformed by 23.08% the S&P500.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 7 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Ironwood Pharmaceuticals had 10 analyst reports since November 27, 2017 according to SRatingsIntel. Mizuho maintained the shares of IRWD in report on Tuesday, January 9 with “Hold” rating. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Neutral” rating by Mizuho on Wednesday, December 6. The rating was maintained by Mizuho with “Hold” on Monday, March 12. The rating was initiated by Berenberg on Thursday, April 19 with “Buy”. Mizuho upgraded the shares of IRWD in report on Wednesday, May 2 to “Buy” rating. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Sell” rating by Bank of America on Friday, January 5.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.73 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

More important recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Nasdaq.com which released: “Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress …” on May 07, 2018, also Seekingalpha.com published article titled: “Your Daily Pharma Scoop: IRWD Division, Jazz sNDA, Siga Adcomm”, Prnewswire.com published: “Daily Technical Summary Reports on Generic Drugs Stocks — Adamas Pharma, Catalent, Diplomat Pharmacy, and …” on May 07, 2018. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was released by: Bizjournals.com and their article: “Ironwood slams Denner’s bid for board seat as proxy fight looms” with publication date: May 02, 2018.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.





Back To Top